Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer (Q36352105)

13 August 2017

1 reference

title

Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer (English)

1 reference

13 August 2017

Camillo Porta

1

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

141-152

1 reference

13 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Rising incidence of renal cell cancer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

The changing natural history of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Defective death receptor signaling as a cause of tumor immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

MHC class I antigens, immune surveillance, and tumor immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

T-cell immunity in the induction and maintenance of a tumour dormant state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Activation of NK cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Extrathymic CD4/CD8 double positive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Effectiveness of very low doses of immunotherapy in advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Cancer dormancy: opportunities for new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.141

Immunotherapy for advanced renal cell cancer.

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425

Identifiers

DOI

10.1586/14737140.6.1.141

1 reference

13 August 2017

1 reference